

Resource Summary Report

Generated by [NIF](#) on Aug 31, 2026

AsPC-1

RRID:CVCL_0152

Type: Cell Line

Proper Citation

RRID:CVCL_0152

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0152

Proper Citation: RRID:CVCL_0152

Description: Cell line AsPC-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Pancreatic ductal adenocarcinoma

Defining Citation: [PMID:1630814](#), [PMID:1764370](#), [PMID:4023565](#), [PMID:6582512](#), [PMID:7182348](#), [PMID:7972006](#), [PMID:8026879](#), [PMID:8194712](#), [PMID:8286197](#), [PMID:9331070](#), [PMID:9665481](#), [PMID:10027410](#), [PMID:10408907](#), [PMID:11115575](#), [PMID:11169959](#), [PMID:11787853](#), [PMID:12692724](#), [PMID:14695172](#), [PMID:15126341](#), [PMID:15367885](#), [PMID:15688027](#), [PMID:15770730](#), [PMID:16912165](#), [PMID:18298655](#), [PMID:18380791](#), [PMID:20037478](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20418756](#), [PMID:21607521](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26216984](#), [PMID:26586397](#), [PMID:26589293](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:27910856](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:32782605](#), [PMID:35839778](#)

Comments: Caution: TP53 mutation indicated incorrectly as being at c.818G>A in PubMed=1630814., Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: AsPC-1

Synonyms: AsPc-1, Aspc-1, ASPC-1, As-PC1, ASPC1, AsPC1, Aspc1, AsPc1

Cross References: BTO:BTO_0001864, CLO:CLO_0001756, EFO:EFO_0002112, MCCL:MCC:0000044, CLDB:cl289, AddexBio:C0018023/5061, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1682, BCRC:60494, BioGRID_ORCS_Cell_line:259, BioSample:SAMN03471961, BioSample:SAMN10988235, cancercellines:CVCL_0152, CCRID:1101HUM-PUMC000214, CCRID:3101HUMTCHu8, Cell_Model_Passport:SIDM00899, CGH-DB:160-1, CGH-DB:9271-4, ChEMBL-Cells:ChEMBL3307994, ChEMBL-Targets:ChEMBL612588, CLS:300158, Cosmic:707247, Cosmic:710851, Cosmic:724645, Cosmic:808166, Cosmic:868239, Cosmic:872994, Cosmic:910702, Cosmic:913308, Cosmic:918050, Cosmic:922255, Cosmic:923164, Cosmic:932514, Cosmic:933515, Cosmic:947398, Cosmic:948371, Cosmic:948740, Cosmic:949230, Cosmic:1006364, Cosmic:1090374, Cosmic:1108341, Cosmic:1198210, Cosmic:1320465, Cosmic:1366285, Cosmic:1477433, Cosmic:1571783, Cosmic:1644318, Cosmic:1995341, Cosmic:2434085, Cosmic:2668289, Cosmic-CLP:910702, DepMap:ACH-000222, ECACC:96020930, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:910702, GEO:GSM206446, GEO:GSM383935, GEO:GSM495808, GEO:GSM621911, GEO:GSM784702, GEO:GSM886870, GEO:GSM887935, GEO:GSM1024396, GEO:GSM1177959, GEO:GSM1177960, GEO:GSM1177961, GEO:GSM1374394, GEO:GSM1374395, GEO:GSM1374396, GEO:GSM1588607, GEO:GSM1588619, GEO:GSM1669603, GEO:GSM1906985, GEO:GSM1906986, GEO:GSM1906987, IARC_TP53:311, IARC_TP53:21127, IBRC:C10154, IGRhCellID:AsPC1, IZSLER:BS TCL 171, KCLB:21682, LiGeA:CCLE_008, LINCS_LDP:LCL-1730, NCBI_Iran:C558, PharmacDB:AsPC1_67_2019, PRIDE:PXD003198, PRIDE:PXD030304, PRIDE:PXD032263, Progenetix:CVCL_0152, PubChem_Cell_line:CVCL_0152, SKY/M-FISH/CGH:1997, Wikidata:Q54750736

ID: CVCL_0152

Record Creation Time: 20220427T215223+0000

Record Last Update: 20260830T002240+0000

Ratings and Alerts

No rating or validation information has been found for AsPC-1.

No alerts have been found for AsPC-1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 894 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Saini P, et al. (2026) Targeting Interactions Between Siglec-10 and α 5 β 1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer. *Cancer research*, 86(1), 99.

Castelli S, et al. (2026) IL-9 signaling redirects CAR T cell fate toward CD8⁺ memory and CD4⁺ cycling states, enhancing antitumor efficacy. *Immunity*, 59(1), 195.

Armstrong A, et al. (2026) Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(3), 611.

Anh DXT, et al. (2026) GlycoChat Uncovers Glycan-Lectin Circuits in the Tumor Microenvironment of Pancreatic Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(14), e14735.

Miyan J, et al. (2026) The combination of BCL-xL PROTAC and mTOR inhibitor sensitizes pancreatic ductal adenocarcinoma to KRAS G12D inhibitor treatment by enhancing apoptosis induction. *bioRxiv : the preprint server for biology*.

Shi X, et al. (2026) Tumor-immune-neural circuit disrupts energy homeostasis in cancer cachexia. *Cancer cell*, 44(5), 949.

Wang J, et al. (2026) Cyclic di-GMP suppresses cancer metastasis by targeting proteasome 26S subunit non-ATPase 3 independently of STING. *Signal transduction and targeted therapy*, 11(1), 44.

Gong D, et al. (2026) GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. *Cell reports*, 45(5), 117314.

Ning W, et al. (2026) A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. *Cell reports. Medicine*, 7(4), 102688.

Qian Y, et al. (2026) Adipogenic transdifferentiation reprograms EMT-high PDAC cells into a post-mitotic adipocyte-like state and limits metastasis. *Cell death & disease*, 17(1).

Ai ZE, et al. (2026) Targeting ADAR1 p150 triggers tumor inhibition and antitumor immunity to overcome immunotherapy resistance. *iScience*, 29(6), 115978.

Shi X, et al. (2026) Tumor-Derived LAMB3 Drives Immunosuppressive LRRC15⁺ Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e20029.

Wu Y, et al. (2026) The Vitamin D3 Analog Calcipotriol Attenuates Pancreatic Cancer Malignancy via Downregulating Thrombospondin 1 in Pancreatic Stellate Cells. *Mediators of inflammation*, 2026(1), e2632235.

De Boni L, et al. (2026) Placing purines in precision medicine: Targeting a metabolic reliance in KRAS-mutant tumors. *iScience*, 29(3), 114954.

Zhang H, et al. (2026) Combining ferroptosis inducers with gemcitabine to enhance treatment efficacy in pancreatic cancer. *Cancer & metabolism*, 14(1).

Shi M, et al. (2026) Transcriptomic landscape of transposable elements reveals LTR7-PLAAT4 as a potential oncogene and therapeutic target in pancreatic adenocarcinoma. *Genome research*, 36(2), 275.

Shrivastava A, et al. (2026) Mutant KRAS-driven selective mRNA translation reveals mechanisms and therapeutic vulnerabilities in cancer. *Cell reports*, 45(6), 117520.

Shen S, et al. (2026) ALDH1A3 promotes the lung metastatic organotropism of pancreatic ductal adenocarcinoma through semaphorin signaling. *iScience*, 29(6), 115950.

Burge RA, et al. (2026) KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. *Cancer research*, 86(8), 1868.

Lu T, et al. (2026) Targeting PAK4 promotes Gemcitabine-induced pyroptosis in pancreatic cancer via NLRP1/caspase-3/GSDME axis. *Communications biology*, 9(1), 260.